Royalty Pharma lets Elan takeover bid expire

by Tom Murphy

Royalty Pharma has let its latest takeover bid for Irish drugmaker Elan lapse as it decided against pressing ahead with a court challenge of a requirement that it withdraw the offer.

Royalty offered earlier this month to pay $13 per share for each Elan share plus up to $2.50 per share in payments based on performance milestones. That totaled about $7.76 billion not counting the milestone payments.

An Irish Takeover Panel required Royalty to withdraw that offer if Elan's shareholders approved a , which they did in a vote announced Monday. New York-based Royalty had planned to challenge the takeover panel's requirement in court, but it said Tuesday it withdrew the judicial review request.

Elan is exploring a sale of the company, and it has said Royalty can participate in its formal sale process.

Royalty, based in New York, is a privately held company that buys royalty interests in drugs and late-stage . It has made several offers to buy Elan this year after initially pitching a deal for $11 per share in February.

A Royalty spokesman declined to comment Tuesday on whether the company will consider another Elan bid.

Elan had said Royalty's latest offer was "wholly inadequate" for its shareholders.

Elan management may be amenable to a deal that values the company at between $15 and $20 per share, Jefferies analyst Corey Davis said in a research note. He thinks Elan may be worth about $19 per share.

Elan had 596.7 million shares outstanding at the end of the first quarter, so $19 per share would equate to a deal worth about $11.34 billion.

In April, Elan sold its interest in the multiple sclerosis treatment to former development partner Biogen Idec Inc. That deal was worth $3.25 billion in cash and recurring .

The drugmaker also attempted to diversify its business through a string of acquisitions, but shareholders rejected those deals. Elan said last week it would explore a sale after it became clear that shareholders would reject the acquisitions.

Elan's shares rose 18 cents to $13.67 in premarket trading Tuesday 25 minutes before the market opening.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Judge halts Royalty Pharma's bid for Elan stock

Jun 04, 2013

Irish drugmaker Elan Corp.'s fight against a takeover bid by Royalty Pharma has spilled into U.S. federal court, where a judge has issued a temporary restraining order preventing Royalty from completing its offer to buy the ...

Recommended for you

Surrogate offers clues into man with 16 babies

3 hours ago

When the young Thai woman saw an online ad seeking surrogate mothers, it seemed like a life-altering deal: $10,000 to help a foreign couple that wanted a child but couldn't conceive.

Nurses go on strike in Ebola-hit Liberia

3 hours ago

Nurses at Liberia's largest hospital went on strike on Monday, demanding better pay and equipment to protect them against a deadly Ebola epidemic which has killed hundreds in the west African nation.

ALS Ice Bucket Challenge arrives in North Korea

Aug 31, 2014

It's pretty hard to find a novel way to do the ALS Ice Bucket Challenge by now, but two-time Grammy-winning rapper Pras Michel, a founding member of the Fugees, has done it—getting his dousing in the center ...

Cold cash just keeps washing in from ALS challenge

Aug 28, 2014

In the couple of hours it took an official from the ALS Association to return a reporter's call for comment, the group's ubiquitous "ice bucket challenge" had brought in a few million more dollars.

Medtronic spends $350M on another European deal

Aug 27, 2014

U.S. medical device maker Medtronic is building stronger ties to Europe, a couple months after announcing a $42.9 billion acquisition that involves moving its main executive offices across the Atlantic, where it can get a ...

User comments